SC
NUVB icon

Sapient Capital’s Nuvation Bio NUVB Stock Holding History

Sapient Capital’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$179K Hold
31,450
– – ﹤0.01% 387
2026
Q1 		$135K Hold
31,450
– – ﹤0.01% 435
2025
Q4 		$281K Hold
31,450
– – ﹤0.01% 346
2025
Q3 		$101K Buy
+31,450
New +$85.7K ﹤0.01% 381

Other funds holding NUVB

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
FWP
Firethorn Wealth Partners Augusta, Georgia $310M AUM 23.22% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
SIC
Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return

Sapient Capital's NUVB Position: Q2 2026 in Review

Sapient Capital held its Nuvation Bio (NUVB) position steady in Q2 2026 at 31,450 shares worth $179K. The position accounts for ﹤0.01% of the portfolio, ranked #387.

Sapient Capital first reported a position in NUVB in Q3 2025 and has held it in 4 quarters since. The position peaked at $281K in Q4 2025. 13 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Sapient Capital held 31,450 shares of Nuvation Bio worth $179K as of Q2 2026.
  • Sapient Capital left its Nuvation Bio share count unchanged in Q2 2026.
  • Nuvation Bio made up ﹤0.01% of Sapient Capital's portfolio in Q2 2026, its #387 holding.
  • Sapient Capital first reported a position in Nuvation Bio in Q3 2025 and has held it in 4 quarters since.
  • Sapient Capital's Nuvation Bio position peaked at $281K in Q4 2025.
  • 13 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Sapient Capital's 13F filing for Q2 2026, filed 9 Jul 2026.